FDA Commissioner Marty Makary articulates a vision for a modernized agency focused on efficiency, AI integration, and faster drug approvals, defending recent workforce reductions. The agency’s new pilot priority voucher program aims to incentivize development addressing national priorities with expedited review timelines. Meanwhile, controversies emerge as HHS cancels biotech grants linked to foreign investment, generating concern about international collaborations. The Advisory Committee on Immunization Practices faces turmoil after member dismissals, raising questions on vaccine policy stability. These regulatory and political developments signal evolving dynamics within the biotech and public health ecosystem.